Clinical trials: Short Gut
Short Bowel Syndrome
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.
- Trial name
- EASE SBS 5 (NCT07197944)
- Testing
- Glepaglutide
- Where
- 33 sites in United States, Austria and 12 more
- Volunteers
- 90 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
The main aims of the study are to assess the safety profile of teduglutide (Revestive®) as well as how many people with Short Bowl Syndrome experience a reduction of parenteral support when treated with teduglutide (Revestive®).
- Trial name
- T-Rex (NCT04883606)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Takeda
Short Bowel Syndrome, Parenteral Nutrition Associated Liver Disease
Study of NST-6179 in Healthy Subjects
A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.
- Trial name
- NCT05181085
- Testing
- NST 6179
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Short Bowel Syndrome
A Phase 2 Trial Testing ZP1848 in Patients With SBS
A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.
- Trial name
- glepaglutide (NCT02690025)
- Testing
- ZP1848
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Zealand Pharma
Short Bowel Syndrome
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
- Trial name
- STARS extend (NCT05018286)
- Testing
- Apraglutide
- Where
- 66 sites in United States, Argentina and 16 more
- Volunteers
- 158 people
- Sponsor
- VectivBio AG
Short Bowel Syndrome
Safety and Efficacy Study in Infant With SBS
The objective of this clinical study is to evaluate the efficacy and safety of NTRA-9620 compared with placebo in pediatric subjects (aged 28 weeks postmenstrual age to 52 weeks old) with SBS following surgical resection
- Trial name
- GIFT (NCT02865122)
- Testing
- NTRA-9620
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- Elgan Pharma Ltd.
Healthy
Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers
The primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (QT, QTc interval).
- Trial name
- NCT01028924
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Nycomed
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care (Intralipid) from 7 up to 90 days to develop Essential Fatty Acid…
- Trial name
- NCT04555044
- Testing
- Clinolipid, Intralipid
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Baxter Healthcare Corporation
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD).
- Trial name
- NCT02476994
- Testing
- Clinolipid, Intralipid
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baxter Healthcare Corporation
Short Bowel Syndrome
Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome
A new Enteric-Coated Cholestyramine (ECC) capsule has been developed to manage diarrhea associated with Short Bowel Syndrome (SBS) in adults.
- Trial name
- NCT04046328
- Testing
- Enteric-Coated Cholestyramine (ECC) Capsule
- Where
- 3 sites in Poland
- Volunteers
- 13 people
- Sponsor
- Pharmascience Inc.
Short Bowel Syndrome
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes.
- Trial name
- STEPS (NCT00798967)
- Testing
- teduglutide
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- Shire
SBS - Short Bowel Syndrome
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE 203799 in 8 patients with SBS. The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 once weekly for 4 consecutive weeks…
- Trial name
- NCT03408132
- Testing
- FE203799
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- GlyPharma Therapeutics
Muscle Invasive Bladder Urothelial Carcinoma
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during…
- Trial name
- ARTIA-Bladder (NCT05700227)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Varian, a Siemens Healthineers Company
Gastrointestinal Tract
Evaluation of Gastrointestinal Comfort Following Regular Consumption of Short-chain Fructo-oligosaccharides (10-20 g Per Day) by Children Aged 6-12 Years
The current intake of dietary fiber by children in France and Europe is below established nutritional recommendations. Therefore, promoting fiber consumption from childhood as part of a diversified diet is crucial.
- Trial name
- FOSTI (NCT06204978)
- Testing
- short-chain fructo-oligosaccharides (dose 1), short-chain fructo-oligosaccharides (dose 2), Baseline
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tereos
Short Bowel Syndrome
A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease
The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revestive®).
- Trial name
- NCT04877431
- Where
- Argentina
- Volunteers
- 45 people
- Sponsor
- Takeda
Short Bowel Syndrome (SBS)
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in…
- Trial name
- NCT05371028
- Testing
- Non-interventional Study
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Takeda
Short Bowel Syndrome
Registry for Participants With Short Bowel Syndrome
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting.
- Trial name
- NCT01990040
- Where
- United States
- Volunteers
- 1,806 people
- Sponsor
- Shire
Short Bowel Syndrome
Proof of Concept Study in Patients With Short Bowel Syndrome
This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide.
- Trial name
- NCT04379856
- Testing
- NM-002
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- 9 Meters Biopharma, Inc.